EF
Therapeutic Areas
Stelexis Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Eganelisib | Higher Risk-MDS and AML | Phase 1 |
| STLX-2012 | Lower Risk-MDS and CMML | Pre-IND to Early Clinical |
Leadership Team at Stelexis Therapeutics
MA
Manuel Aivado, M.D., Ph.D.
President and Chief Executive Officer
RA
Rossitza Alargova, Ph.D.
Head of CMC